Evidence map›Paper›PMID 29691241›Full record

ArticleBMJ open2018

Modern contraceptive use among HIV-infected women attending HIV care centres in Togo: a cross-sectional study.

Issifou Yaya, Akouda Akessiwè Patassi, Dadja Essoya Landoh, Essodjèlouna Manani Bignandi, Kanfitine Kolani, Abdel-Daim Daou Namoro, P'Niwè Massoubayo Patchali, Lihanimpo Djalogue, Didier Koumavi Ekouevi, Bayaki Saka

Abstract read
In one paragraph

Article in BMJ open, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed, 3 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 3 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Issifou YayaAix Marseille University, INSERM, IRD, SESSTIM, Sciences Economiques & Sociales de la Santé & Traitement de l'Information Médicale, Marseille, France.
Akouda Akessiwè PatassiService de maladies infectieuses, CHU Sylvanus Olympio, Université de Lomé, Lomé, Togo.
Dadja Essoya LandohWorld Health Organization, Country Office of Togo, Lomé, Togo.
Essodjèlouna Manani BignandiService de médecine générale, CHR Tomdè, Kara, Togo.
Kanfitine KolaniService de gynécologie-obstétrique, Clinique Biasa, Lomé, Togo.
Abdel-Daim Daou NamoroGynécologie-obstétrique, Évaluation de programmes, Québec, Canada.
P'Niwè Massoubayo PatchaliDivision de la Santé Communautaire, Ministère de la Santé, Lomé, Togo.
Lihanimpo DjalogueService de médecine interne, CHU, Kara, Togo.
Didier Koumavi EkoueviDépartement de Sante Publique, Université de Lomé, Lomé, Togo.
Bayaki SakaService de dermatologie, CHU Sylvanus Olympio, Lomé, Togo.

Funding

World Health Organization 001
6 · The paper itself

Abstract

introductionContraceptive use among HIV-infected women in Togo is poorly documented. We aim at assessing the prevalence of modern contraceptive use and associated factors among HIV-infected women in Togo.

designCross-sectional study.

settingThe study was conducted in five HIV care centres in the Centrale and Kara regions in Togo.

participantsWe included 461 HIV-positive women aged between 15 and 49 years and who were sexually active.

main outcome measureThe outcome variable was HIV-infected women who were using modern contraceptive methods.

resultsA total of 461 HIV-infected women were interviewed, with an average age of 34.3 (±7.1). Among them, 332 (73.1%) women reported using contraceptive methods, mostly condom alone (74.7%) or in combination with hormonal contraceptive (16.9%). In multivariate analysis, education level (primary: adjusted OR (aOR)=1.99, 95% CI (1.05 to 3.76); secondary level and higher: aOR=3.95, 95% CI (2.03 to 7.67)), WHO clinical stage (stage II: aOR=0.7, 95% CI (0.37 to 1.33)), follow-up in private care facilities (aOR=2.54, 95% CI (1.22 to 5.29)) and having a child (aOR=2.51, 95% CI (1.41 to 4.5)) were associated with higher contraceptive use, while marital status (living in union: aOR=0.45, 95% CI (0.28 to 0.74)) and WHO stages III and IV (aOR=0.47, 95% CI (0.24 to 0.94)) were associated with lower contraceptive use.

conclusionAbout three-quarters of sexually active HIV-infected women in Togo were using contraceptive methods, and private health facilities favoured this contraceptive use. It is important to strengthen the implementation of interventions to increase the incentives for HIV-infected women to use contraception in Togo.

Indexed as

Contraception BehaviorContraceptive AgentsHIV InfectionsAdolescentAdultContraceptionCross-Sectional StudiesFemaleHumansMiddle AgedTogoYoung AdultContraceptive Agentscontraception useHIV-infected womenTogo

Identifiers

PMID29691241
PMCPMC5922471

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.